An observational study in Primary Hypercholesterolemia and Mixed Dyslipidemia, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 40 sites in 8 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Hypercholesterolemia by Novartis — 6 open to participants now, 10 under way, 5 of them phase 3. Hypercholesterolemia · Novartis.
Among the 36 studies in Hypercholesterolemia by Novartis, this one is the 6th largest by enrollment of the 10 observational ones that give a count, is one of 4 that started in 2022, is one of 10 observational ones, and was the 20th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →6 of the 36 studies in Hypercholesterolemia by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in Argentina, Brazil
Ages 18–100
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 20 more countries
Ages 6–11
By country, each count listing its studies:
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 847 is below the median of 1,000 across 145 observational studies indexed under Hypercholesterolemia.
Median enrollment 385 across the 26 interventional studies, 1,174 across the 10 observational. Of the 26 that completed or were terminated, 10 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
4 of the studies in Hypercholesterolemia by Novartis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT05399992Novartis PharmaceuticalsStudy Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | 2026-11-23 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
| NCT07610278Novartis PharmaceuticalsA Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | 2027-04-28 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Hypercholesterolemia by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical practice.
Patients will be enrolled over a period of 23 months, and followed for up to 24 months to assess for study outcomes.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
This study's enrollment of 847 is below the median of 1,000 across 145 observational studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The study population will consist of adult participants with an underlying diagnosis of Atherosclerotic Cardiovascular Disease (ASCVD), ASCVD risk equivalent (ASCVD RE), or Heterozygous familial hypercholesterolemia (HeFH) and elevated levels of Low density lipoprotein - Cholesterol (LDL-C)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants prescribed inclisiran alone or with other LLTs as per approved label
Other: Inclisiran
Prospective observational study. There is no treatment allocation. Patients who are eligible to receive inclisiran will be enrolled into this study.
Percentage change in LDL-C from baseline to 10 months
Percentage change in Low density lipoprotein - Cholesterol (LDL-C)
Time frame: Baseline, 10 months
Percentage change in LDL-C from baseline
Percentage change in LDL-C from baseline is collected
Time frame: Baseline, month 4, month 16, month 22
Percentage change in LDL-C from baseline by ≥50%
Percentage change in LDL-C from baseline by ≥50%
Time frame: Month 4, month 10, month 16, month 22
Percentage change in LDL-C from baseline by ≥30%
Percentage change in LDL-C from baseline by ≥30%
Time frame: Month 4, month 10, month 16, month 22
Proportion of participants achieving LDL-C<55 mg/dL
Proportion of participants achieving LDL-C\<55 mg/dL
Time frame: Proportion of participants achieving LDL-C<55 mg/dL Month 4, month 10, month 16 and month 22
Proportion of participants achieving LDL-C<70 mg/dL
Proportion of participants achieving LDL-C\<70 mg/dL
Time frame: Month 4, month 10, month 16 and month 22
Time-averaged percentage change in LDL-C from baseline
Time-averaged percentage change in LDL-C from baseline
Time frame: Baseline, month 4, month 10, month 16 and month 22
Proportion of participants achieving ≥50% reduction in LDL- C at month 10 and maintaining this at 16, 22 and 24 months
Proportion of participants achieving ≥50% reduction in LDL C at month 10 and maintaining this at 16, 22 and 24 months
Time frame: Month 10, month 16, month 22 and month 24
Proportion of participants achieving ≥30% reduction in LDL C from baseline to 10 months and maintaining until 24 months
Proportion of participants achieving ≥30% reduction in LDL C from baseline to 10 months and maintaining until 24 months
Time frame: Baseline, month 10, month 24
Proportion of participants achieving <55 mg/dL and <70 mg/dL in LDL-C at 10 months and maintaining until 24 months
Proportion of participants achieving \<55 mg/dL and \<70 mg/dL in LDL-C at 10 months and maintaining until 24 months
Time frame: Month 10 and month 24
Inclisiran cohort : Percentage of days covered by inclisiran
Inclisiran cohort : Percentage of days covered by inclisiran
Time frame: 12 months and 24 months
Inclisiran cohort : Mean PDC
Mean Proportion of Days Covered (PDC) for inclisiran cohort is collected
Time frame: 12 months and 24 months
Inclisiran cohort : Proportion of participants with a PDC ≥ 80%
Proportion of participants with a PDC ≥ 80% (sensitivity: 90%/100%)
Time frame: 12 months and 24 months
Proportion of participants remaining on initial baseline therapy
Proportion of patients remaining on initial baseline therapy in the inclisiran cohort
Time frame: Baseline, month 12 and month 24
Time to discontinuation of any newly initiated therapies
Time to discontinuation of any newly initiated therapies
Time frame: Month 12 and month 24
Time to discontinuation of any newly initiated therapies by specific LLT
Time to discontinuation of any newly initiated therapies by specific LLT
Time frame: Month 12 and month 24
Change from baseline in scores from the TSQM (modified) instrument
The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4 is an instrument to assess patients' satisfaction with medication, providing scores on four scales - side effects, effectiveness, convenience and global satisfaction. TSQM V1.4 has a score range of 0 to 100 with with higher scores indicating higher patient satisfaction with medication.
Time frame: Baseline, month 12 and month 24
Descriptive adherence data based on Adherence AAQ
Adherence Assessment Questionnaires (AAQ) measures the degree of identified non-adherence to LLT therapy. AAQ has a score range from 0 (not adherent at all) to 100 (absolute adherent).
Time frame: Month 12 and month 24
Descriptive adherence data based on ABQ
Adherence Barriers Questionnaire (ABQ) is an instrument for identifying specific barriers to medication-related adherence. ABQ is a descriptive analysis. The number and proportion of patients affected by each barrier will be reported for inclisiran participants.
Time frame: Month 12 and month 24
Started Sep 2022 (actual). Primary completion is estimated for Nov 2026, 50 months after the start.
Of 51 observational studies under Hypercholesterolemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 59. This study's planned 50 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Oct 2026 → Nov 2026 and completion Oct 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.